Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ALMS Stock Forecast 2025-2026
$4.28
Current Price
$234.50M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ALMS Price Targets
+577.6%
To High Target of $29.00
+402.3%
To Median Target of $21.50
+227.1%
To Low Target of $14.00
ALMS Price Momentum
-8.9%
1 Week Change
-24.1%
1 Month Change
0.0%
1 Year Change
-45.5%
Year-to-Date Change
-68.4%
From 52W High of $13.53
+34.6%
From 52W Low of $3.18
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Alumis (ALMS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALMS and similar high-potential opportunities.
Latest ALMS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, ALMS has a bullish consensus with a median price target of $21.50 (ranging from $14.00 to $29.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $4.28, the median forecast implies a 402.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Thomas Smith at Leerink Partners, projecting a 577.6% upside. Conversely, the most conservative target is provided by Mitchell Kapoor at HC Wainwright & Co., suggesting a 227.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALMS Analyst Ratings
5
Buy
0
Hold
0
Sell
ALMS Price Target Range
Low
$14.00
Average
$21.50
High
$29.00
Current: $4.28
Latest ALMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 22, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $14.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $15.00 |
| Mar 20, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $19.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $19.00 |
| Jan 30, 2025 | Oppenheimer | Jeff Jones | Outperform | Initiates | $32.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $26.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 14, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $26.00 |
| Oct 31, 2024 | Baird | Brian Skorney | Outperform | Initiates | $25.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Initiates | $30.00 |
| Aug 19, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $0.00 |
| Jul 23, 2024 | Morgan Stanley | Terence Flynn | Overweight | Initiates | $36.00 |
| Jul 23, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Initiates | $0.00 |
| Jul 23, 2024 | Guggenheim | Yatin Suneja | Buy | Initiates | $32.00 |
| Jul 23, 2024 | Leerink Partners | Thomas Smith | Outperform | Initiates | $29.00 |
Alumis Inc. (ALMS) Competitors
The following stocks are similar to Alumis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alumis Inc. (ALMS) Financial Data
Alumis Inc. has a market capitalization of $234.50M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -198.7%.
Valuation Metrics
Market Cap
$234.50M
Enterprise Value
$-24,677,640
P/E Ratio
0.0x
PEG Ratio
-0.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+123.8%
Current Ratio
6.0x
Debt/Equity
11.8x
ROE
-198.7%
ROA
-87.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Alumis Inc. (ALMS) Business Model
About Alumis Inc.
What They Do
Develops innovative therapies for autoimmune diseases.
Business Model
Alumis Inc. generates revenue through the research, development, and commercialization of novel therapeutic solutions targeting autoimmune diseases. The company collaborates with leading researchers and utilizes advanced scientific techniques to innovate targeted treatments that address unmet medical needs.
Additional Information
Alumis Inc. is recognized for its commitment to innovation and improving patient outcomes. Its distinct methodology in approaching autoimmune disorders contributes to a diverse range of treatment options in the healthcare market, positioning the company as a key player in biopharmaceutical advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
168
CEO
Mr. Martin Babler Ph.D.
Country
United States
IPO Year
N/A
Website
www.alumis.comAlumis Inc. (ALMS) Latest News & Analysis
Latest News
Quick Summary
ACELYRIN stockholders will now own 48% of the combined company post-merger, while Alumis stockholders will hold 52%. A special meeting is scheduled for May 13, 2025.
Why It Matters
Increased ownership stakes for ACELYRIN stockholders post-merger enhance value potential, while the combined company is positioned for growth with late-stage assets, signaling potential long-term profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
U.S. stocks rose on Monday, with the Nasdaq Composite increasing by over 200 points.
Why It Matters
Rising U.S. stocks, particularly the Nasdaq's significant gain, signals investor confidence and potential growth in tech sectors, influencing market sentiment and investment decisions.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Kahn Swick & Foti, LLC is investigating Acelyrin, Inc.’s proposed sale to Alumis Inc., where Acelyrin shareholders would receive 0.4274 shares of Alumis stock per share owned.
Why It Matters
The investigation into Acelyrin's sale to Alumis may indicate potential issues with the deal's valuation or process, affecting investor confidence and share prices of both companies.
Source: Business Wire
Market Sentiment:
Neutral
3 Biopharmaceutical Stocks Bucking the Sell-Off
18 days ago
Quick Summary
The S&P 500 fell about 10% in early April 2025 due to tariffs, prompting cash-rich investors to seek resilient companies amidst market uncertainty.
Why It Matters
Tariffs causing a 10% drop in the S&P 500 signals potential buying opportunities. Identifying resilient companies could lead to strategic investments amid market volatility.
Source: MarketBeat
Market Sentiment:
Negative
Top 3 Health Care Stocks That May Crash In Q2
21 days ago
Quick Summary
As of April 7, 2025, three health care stocks are signaling potential concerns for investors who prioritize momentum in their trading strategies.
Why It Matters
Warning signals in health care stocks may indicate potential downturns, impacting momentum-driven strategies and prompting investors to reevaluate their positions for risk management.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Alumis Inc. and ACELYRIN, INC. plan to merge, with stockholder benefits anticipated from a strong late-stage portfolio and balance sheet. The merger is expected to finalize in Q2 2025.
Why It Matters
The merger signals potential growth and innovation in biopharmaceuticals, enhancing value for shareholders through a robust portfolio and financial stability. Completion in 2025 could drive stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ALMS Stock
What is Alumis Inc.'s (ALMS) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Alumis Inc. (ALMS) has a median price target of $21.50. The highest price target is $29.00 and the lowest is $14.00.
Is ALMS stock a good investment in 2025?
According to current analyst ratings, ALMS has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALMS stock?
Wall Street analysts predict ALMS stock could reach $21.50 in the next 12 months. This represents a 402.3% increase from the current price of $4.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alumis Inc.'s business model?
Alumis Inc. generates revenue through the research, development, and commercialization of novel therapeutic solutions targeting autoimmune diseases. The company collaborates with leading researchers and utilizes advanced scientific techniques to innovate targeted treatments that address unmet medical needs.
What is the highest forecasted price for ALMS Alumis Inc.?
The highest price target for ALMS is $29.00 from Thomas Smith at Leerink Partners, which represents a 577.6% increase from the current price of $4.28.
What is the lowest forecasted price for ALMS Alumis Inc.?
The lowest price target for ALMS is $14.00 from Mitchell Kapoor at HC Wainwright & Co., which represents a 227.1% increase from the current price of $4.28.
What is the overall ALMS consensus from analysts for Alumis Inc.?
The overall analyst consensus for ALMS is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.50.
How accurate are ALMS stock price projections?
Stock price projections, including those for Alumis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 9:46 AM UTC